Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

NCT04720183
terminatedphase_2

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

NCT04700280
completedphase_2

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

NCT04577794
completedphase_2

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04577781

Clinical Trials (4)

Showing 4 of 4 trials
NCT04720183Phase 1

Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

Completed
NCT04700280Phase 2

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)

Terminated
NCT04577794Phase 2

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Ulcerative Colitis

Completed
NCT04577781Phase 2

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4